ADHD Drug Indirect Purchasers Lose Antitrust Class Cert. Bid

By Hannah Albarazi (August 21, 2019, 9:43 PM EDT) -- A Massachusetts federal judge on Wednesday refused to grant class certification to two classes of parents and caretakers accusing the pharmaceutical companies Actavis and Shire of antitrust violations, saying they delayed sale of the ADHD medication Intuniv, causing consumers to pay inflated prices.

U.S. District Judge Allison D. Burroughs denied the indirect purchaser plaintiffs' motion for class certification, saying they "have not put forth a reasonable and workable plan to weed out uninjured class members."

The drug manufacturers had argued that because thousands of proposed class members suffered no apparent injury from the generic delay — either because they were loyal...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!